Candidates with prediabetes are increasingly accepted as living kidney donors. However, data specific to the outcomes of living kidney donors with prediabetes is scarce. In this study, we aimed to investigate the outcome of living kidney donors with prediabetes. We also aimed to evaluate the utilization of baseline HbA1c to identify donors at high risk for developing diabetes during the post-donation follow-up period.
INTRODUCTION AND OBJECTIVES:
Candidates with prediabetes are increasingly accepted as living kidney donors. However, data specific to the outcomes of living kidney donors with prediabetes is scarce. In this study, we aimed to investigate the outcome of living kidney donors with prediabetes. We also aimed to evaluate the utilization of baseline HbA1c to identify donors at high risk for developing diabetes during the post-donation follow-up period.
METHODS: Donors with both normal FPG and HbA1c results were included in the control donor group, whereas those with either an FPG or HbA1c result in the prediabetic range were included in the lowrisk prediabetic donor group and those with both FPG and HbA1c results in the prediabetic range were included in the high-risk prediabetic donor group.
RESULTS: Of the 93 donors included in the study, 46 (49.5%) were included in the control donor group, 31 (31.6%) in the low-risk prediabetic donor group, and 16 (16.3%) in the high-risk prediabetic donor group. The donors were followed for a mean of 75.9AE23.3 months. Age and baseline triglyceride and LDL-cholesterol levels were significantly lower in the control group compared to the other two groups. Estimated GFR was not significantly different at pre-donation or at any of the yearly follow-up visits across the three groups. On Log-rank test the high-risk group was significantly more likely to be diagnosed with T2DM after donation (high-risk versus lowrisk, p[0.008; high-risk versus control, p<0.001; low-risk versus control, p[0.08) .
CONCLUSIONS: Donors with prediabetes are not at an increased risk during the immediate post-donation period. HbA1c in conjunction with FPG can stratify the risk of being diagnosed as T2DM during follow-up in prediabetic donors. 
